Medication info
Sitafomin XR Extended-Release Tablet 50/500 mg

Sitafomin XR Extended-Release Tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Daehan New Pharm Co., Ltd.
Appearance
A bright blue, oval-shaped, bilayered extended-release film-coated tablet.
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202202026 · Approved 2022.05.13 · Insurance code 669908290

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, to reduce gastrointestinal adverse reactions caused by metformin. The dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the drug did not dissolve completely and was excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in their stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). Take 1 tablet of this drug 100/1000 mg extended-release tablets once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets at the same time once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin must not be switched to this drug (see Precautions, 2. Patients in whom this drug is contraindicated). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is a total daily dose of sitagliptin 100 mg, and the initial dose of metformin should be based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with another oral antihyperglycemic agent. Any change in a type 2 diabetes treatment regimen may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug must not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Patients in whom this drug is contraindicated).

Ingredients

Manufacturer
Daehan New Pharm Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes by combining sitagliptin and metformin. It is particularly effective for those managing their diet and engaging in exercise therapy, assisting in maintaining more stable blood sugar levels. This enables more effective management of diabetes and supports a healthy lifestyle.

How to take

Adult dose

In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, to reduce gastrointestinal adverse reactions caused by metformin. The dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the drug did not dissolve completely and was excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in their stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). Take 1 tablet of this drug 100/1000 mg extended-release tablets once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets at the same time once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin must not be switched to this drug (see Precautions, 2. Patients in whom this drug is contraindicated). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is a total daily dose of sitagliptin 100 mg, and the initial dose of metformin should be based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with another oral antihyperglycemic agent. Any change in a type 2 diabetes treatment regimen may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug must not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Patients in whom this drug is contraindicated).

Precautions

This medication contains two components, sitagliptin and metformin, used in diabetes treatment. First, sitagliptin may rarely cause severe allergic reactions, so if symptoms such as rash, difficulty breathing, or swelling of the face or neck occur after taking this medication, discontinue use immediately and consult a physician. Additionally, sitagliptin may cause pancreatitis, which is inflammation of the pancreas, so it is important to inform medical personnel immediately if abdominal pain, nausea, or vomiting occur during treatment. Metformin can rarely cause lactic acidosis, a serious metabolic anomaly, which might present with symptoms such as muscle pain, difficulty breathing, fatigue, and abdominal pain. If these symptoms arise, discontinue use immediately and visit a hospital. This medication should not be given to patients with impaired kidney function, severe infections or dehydration, acute heart failure or myocardial infarction, or those with compromised liver function. Moreover, this medication should be temporarily discontinued before and after tests using iodine contrast agents to reduce the risk of kidney damage and lactic acidosis, and it should be resumed only after confirming normal kidney function post-examination. Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this medication. During the use of this medication, it is important to maintain a regular meal schedule and exercise for blood sugar control. If symptoms of hypoglycemia (dizziness, cold sweat, severe hunger, etc.) occur, immediate action should be taken. Furthermore, alcohol consumption may increase the risk of lactic acidosis, so it is advisable to avoid drinking during the treatment period. Regular kidney function and blood tests should be conducted, particularly for elderly patients or those with slight reductions in kidney function who require closer monitoring. Finally, it is important to report any new symptoms or adverse reactions that occur during treatment to the medical staff immediately.

Side effects

  • Severe allergic reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
Show 21 more
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis
  • elevated liver enzymes
  • acute renal failure
  • hypoglycemic episodes
  • peripheral edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it is important to store it in a tightly sealed container. The storage temperature should be maintained between 1 and 30 degrees Celsius (room temperature), avoiding extremely hot or cold places.

Appearance and packaging

Appearance

A bright blue, oval-shaped, bilayered extended-release film-coated tablet.

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.